Journal of International Psychiatry

Abstract Objective: To investigate venlafaxine extended release tablets in the treatment of major depressive disorder epilepsy patients and observe the effect on serum DA patients, 5-HT and proinflammatory cytokines. Methods: selected from our hospital in January 2013~December 2015 during epileptic patients with depression in 92 patients, were randomly divided into observation group 46 cases and control group of 46 patients. Control group with fluoxetine hydrochloride capsules treatment, observation group received venlafaxine extended release tablets in the treatment. The treatment lasted two months. Comparing two groups of treatment efficacy, before and after treatment HAMA and HAMD scores, serum DA and 5-HT levels of serum IL-1β, and IL-4 levels and adverse reactions. Results: The observation group total efficiency of the control group (P<0.05); two groups of HAMA and HAMD score after treatment decreased (P<0.05); the observation group HAMA and HAMD scores after treatment lower than the control group (P<0.05); Two groups serum DA and 5-HT levels decreased after treatment (P<0.05); The observation groupafter serum DA and 5-HT level of lower than the control group (P<0.05); Two groups serum IL-1β, and IL-4 levels decreased after treatment (P<0.05); The observation groupafter serum IL-1β and IL-4 level of lower than the control group (P<0.05); two groups showed no electrocardiogram, blood, urine, liver and kidney dysfunction, and no serious adverse reactions of drugs.Conclusion: Venlafaxine extended release tablets in the treatment of major depressive disorder in patients with epilepsy significant effect, its effect may be reduced with the DA, 5HT, IL-1β, and IL-4 levels correlated, and no significant adverse reactions, is worth studying.

Keywords: venlafaxine tablets; epileptic depression; efficacy; dopamine; serotonin; inflammatory cytokines